Evidence map›Paper›PMID 29197997›Full record

ArticleDiabetologia2018

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na

Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 332 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
332citing papers in PubMed, 8 pooled it
27.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

332 citing papers in PubMed, 8 syntheses or guidelines pooled it, 586 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

272 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Laween UthmanLaboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Antonius BaartscheerDepartment of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Boris BleijlevensDepartment of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Cees A SchumacherDepartment of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Jan W T FioletDepartment of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Anneke KoemanLaboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Milena JancevLaboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Markus W HollmannLaboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Nina C WeberLaboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Ruben CoronelDepartment of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Coert J ZuurbierLaboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. c.j.zuurbier@amc.uva.nl.
University of Amsterdam · NLAcademic Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisSodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) constitute a novel class of glucose-lowering (type 2) kidney-targeted agents. We recently reported that the SGLT2i empagliflozin (EMPA) reduced cardiac cytosolic Na

methodsCardiac NHE activity and [Na

resultsEMPA, DAPA and CANA inhibited NHE activity (measured through low pH recovery after NH CONCLUSIONS/

interpretationEMPA, DAPA and CANA directly inhibit cardiac NHE flux and reduce [Na

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAminopyridinesAnimalsBenzhydryl CompoundsCanagliflozinCytosolGlucosidesMaleMiceMyocytes, CardiacSodiumSodium-Glucose Transporter 2Sodium-Hydrogen ExchangersSulfonamidesAminopyridinesBenzhydryl CompoundsCanagliflozindapagliflozinempagliflozinGlucosidesN-ethyl-2-((6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)amino)-N-pyridin-3-ylmethyl-acetamideSodiumSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsSodium-Hydrogen ExchangersSulfonamidesCardiacDiabetesHeart failureNa+/H+ exchangerSGLT2iSodiumVasodilation

Identifiers

PMID29197997
PMCPMC6448958
OpenAlexW2772835527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.